Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-7101A in children with uncomplicated influenza
NCT06669351Phase 3Terminated
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Seloxavir marboxil in influenza (3 arms), sponsored by Zenshine Pharmaceuticals Co., Ltd. Primary endpoints: Pharmacokinetic parameters of ZX-7101A and its metabolite ZX-7101 in plasma at 336 hours and Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0. Started Oct 2024; status: terminated.
02
Drugs
Seloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06669351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669351.